Supernus Pharmaceuticals (NASDAQ:SUPN) Lowered to Neutral Rating by Cantor Fitzgerald

Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) was downgraded by equities research analysts at Cantor Fitzgerald from an “overweight” rating to a “neutral” rating in a research report issued on Wednesday, Marketbeat Ratings reports. They currently have a $36.00 price target on the specialty pharmaceutical company’s stock, down from their previous price target of $57.00. […]